North American AIDS Cohorts Collaboration on Research and Design (NAACCORD) Renewal

北美艾滋病队列研究与设计合作 (NAACCORD) 更新

基本信息

批准号：
9980769
负责人：
Keri Nicole Althoff
金额：
$ 293.91万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2006
资助国家：
美国
起止时间：
2006-07-01 至 2021-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9980769
关键词：
AIDS/HIV problem Acquired Immunodeficiency Syndrome Address Adult Aging American Antiviral Agents Antiviral Therapy Area Basic Science Biometry Canada Caring Clinical Clinical Research Collaborations Continuity of Patient Care Data Demographic Factors Development Diabetes Mellitus Disease Epidemic Epidemiology Funding Future Geography HIV HIV Infections HIV/HCV Hepatitis C Hepatitis C Therapy Hepatitis C co-infection Hyperlipidemia Hypertension Incidence Individual Informatics Infrastructure Intervention Kidney Diseases Life Life Expectancy Liver diseases Measures Monitor Myocardial Infarction North America Outcome Participant Pattern Persons Population Positioning Attribute Prognostic Factor Research Research Design Research Personnel Resources Risk Factors Sample Size Site Statistical Methods Talents Time Time trend Treatment outcome Viral age related antiretroviral therapy base cancer risk care outcomes clinical care clinical research site cohort comorbidity contextual factors design epidemiologic data experience follow-up improved multidisciplinary multiple chronic conditions prognostic public health relevance response social standard of care treatment strategy uptake virology

项目摘要

DESCRIPTION (provided by applicant): The North American-AIDS Cohort Collaboration on Research and Design (NA-ACCORD) has represented Region 1 of the leDEA initiative since 2006. The 22 single and multi-site clinical and classical epidemiologic HIV cohorts of the NA-ACCORD encompass most HIV/AIDS cohorts within the US and Canada. Over 200 sites in the US and Canada contribute data collected from 150,000 HIV-infected participants. We have established a strong collaborative infrastructure that capitalizes on the talents and expertise of multi-disciplinary group of investigators that span basic science, clinical research, epidemiology, data informatics and biostatistics. We have been highly productive in addressing our previous Aims and expanding our scientific focus to several areas of contemporary importance in HIV in North America, and our collaboration is well- positioned to answer the key questions in practice today. We have three broadly-defined aims for the next funding cycle: Aim 1: Assess and characterize the clinical course of HIV infection in North America, with a focus on aging, major non-AIDS comorbidities and life-expectancy. Aim 2: Characterize the HIV Care Continuum in North America from engagement in HIV care through viral suppression, and extend the Continuum to include long-term retention, utilization of ART to clinical outcomes and life-expectancy. Aim 3: Assess the impact of new direct-acting antivirals (DAAs) on the progression and outcomes of HIV and hepatitis C (HCV) disease in HIV-HCV co-infected persons. The NA-ACCORD is a world-class collaboration of established HIV cohorts well-positioned to provide definitive answers to these issues of contemporary relevance in the U.S. and Canada. In addition, we will expand our collaboration with other leDEA regions to both inform future experience in resource-limited regions as the treatment of the epidemics mature, and to identify and understand differences in treatment, outcomes and prognostic factors that might inform future research and clinical care globally.

描述（由适用提供）：北美援助研究与设计方面的北美辅助团队合作（NA-ACCORD）自2006年以来代表了Ledea倡议的第1区。22个单位和多站点的临床和多站点临床和经典的流行病学HIV同胞在NA-Accord大多数HIV/AIDS COHORTS内部的NA-Accord coplys in and and and Cana和Cana Canca中。美国和加拿大的200多个站点贡献了从15万名HIV感染的参与者收集的数据。我们已经建立了一个强大的协作基础设施，该基础设施利用了跨越基础科学，临床研究，流行病学的多学科研究人员的才能和专业知识，数据信息和生物统计学。我们在解决以前的目标并将科学重点扩展到当代在北美的艾滋病毒中的几个领域方面的生产力很高，我们的合作良好，可以回答当今实践中的关键问题。我们有三个针对下一个融资周期的广泛定义的目标：目标1：评估和表征北美艾滋病毒感染的临床疗程，重点是老化，主要的非辅助性合并症和预期生活。 AIM 2：特征北美的HIV护理连续体从参与艾滋病毒护理到病毒抑制，并将连续性扩展到包括长期保留，艺术利用到临床成果和预期生命。 AIM 3：评估新的直接作用抗病毒药（DAA）对HIV和HIV-HCV共同感染的人的HIV和肝炎（HCV）疾病的进展和结果的影响。 NA-Accord是一场世界一流的合作，其位置良好的既定艾滋病毒队列，可为美国和加拿大的当代相关性提供明确的答案。此外，我们将扩大与其他Ledea地区的合作，以供资源有限地区的未来经验作为对流行病成熟的治疗的未来经验，并确定和理解可能在全球范围内为未来的研究和临床护理提供依据的治疗，结果和预后因素的差异。